Keyword: Merck & Co.

If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.

BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.

In a phase 1/2 study, Astellas and Affinivax's MAPS-based vaccine will be tested head-to-head against Pfizer's Prevnar 13.

Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.

Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.

Content is king, and it’s especially important in pharma. That’s why point-of-care agency Mesmerize has inked a deal with a top magazine publisher.

Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.

Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.

Takeda's dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.

The adjuvant use of I-O therapies could be a $29 billion market, currently led by BMS and Roche, according to Credit Suisse analysts.